Aridis Pharmaceuticals Inc To Provide a Business and Pipeline Update Transcript
Good afternoon and welcome to the Aridis Pharmaceuticals corporate update call. As a reminder, this call is being recorded. (Operator Instructions)
On the call today are Dr. Bruno Francois, lead principal investigator of the AR-301-002 study; Dr. Hasan Jafri, Aridis Pharmaceuticals' Chief Medical Officer; and Dr. Vu Truong, CEO of Aridis. The company would like to remind everyone that various remarks about future expectations, plans and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
Aridis cautions that these forward-looking statements are subject to risks and uncertainties that may cause their actual results to differ materially from those indicated, including risks described in the company's. filings with the SEC. Any forward-looking statements made on the conference call speak only as of today's date, Wednesday, January 25, 2023, and Aridis does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after today. A replay of today's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
